Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets

Vaccine

Volumn 33, Issue 18, 2015, Pages 2152-2158

  Liu, Ye V ^a   Massare, Michael J ^a   Pearce, Melissa B ^c   Sun, Xiangjie ^c   Belser, Jessica A ^c   Maines, Taronna R ^c   Creager, Hannah M ^c,d   Glenn, Gregory M ^a   Pushko, Peter ^b   Smith, Gale E ^a   Tumpey, Terrence M ^c  

^a NOVAVAX INC   (United States)

^b Medigen Inc   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Avian influenza; Ferret; Influenza; Vaccine; Virus

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VACCINE; CHOLESTEROL; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; ISCOMATRIX; PHOSPHOLIPID; SAPONIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; FERRET; HEMAGGLUTINATION INHIBITION; IMMUNITY; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; MALE; NONHUMAN; PRIORITY JOURNAL; TRACHEITIS; VIRION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; BLOOD; CHINA; DISEASE MODEL; DRUG COMBINATION; GENETICS; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VIROLOGY; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHINA; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; PHOSPHOLIPIDS; SAPONINS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL LOAD;

EID: 84926421063     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.009     Document Type: Article

References (43)

1. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A(H7N9) virus. N Engl J Med 2013, 368:1888-1897.
2. Centers for Disease Control and Prevention Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013. MMWR Morb Mortal Wkly Rep 2013, 62(May (18)):366-371.
3. Lee R.T., Gunalan V., Van T.D., Le L.T., Eisenhaber F., Maurer-Stroh S. A new piece in the puzzle of the novel avian-origin influenza A(H7N9) virus. Biol Direct 2013, 8:26.
4. Lam T.T., Wang J., Shen Y., Zhou B., Duan L., Cheung C.L., et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013, 502:241-244.
5. Joseph T., McAuliffe J., Lu B., Vogel L., Swayne D., Jin H., et al. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 2008, 378:123-132.
6. WHO Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines against avian influenza A(H7N9) virus 2013.
7. Pushko P., Pearce M.B., Ahmad A., Tretyakova I., Smith G., Belser J.A., et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 2011, 29:5911-5918.
8. Tretyakova I., Pearce M.B., Florese R., Tumpey T.M., Pushko P. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology 2013, 442:67-73.
9. Rudenko L., Isakova-Sivak I., Donina S. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine 2013, 31:4702-4705.
10. Smith G.E., Flyer D.C., Raghunandan R., Liu Y., Wei Z., Wu Y., et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31:4305-4313.
11. Galarza J.M., Latham T., Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005, 18:244-251.
12. Kang S.M., Pushko P., Bright R.A., Smith G., Compans R.W. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 2009, 333:269-289.
13. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83:5726-5734.
14. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
15. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
16. Quan F.S., Vunnava A., Compans R.W., Kang S.M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS ONE 2010, 5(2):e9161.
17. Ross T.M., Mahmood K., Crevar C.J., Schneider-Ohrum K., Heaton P.M., Bright R.A. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS ONE 2009, 4(6):e6032.
18. Maraskovsky E., Schnurr M., Wilson N.S., Robson N.C., Boyle J., Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009, 87:371-376.
19. Fries L.F., Smith G.E., Glenn G.M. A recombinant virus like particle influenza A(H7N9) vaccine. N Engl J Med 2013, 369:2564-2566.
20. Huang S.S., Banner D., Fang Y., Ng D.C., Kanagasabai T., Kelvin D.J., et al. Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS ONE 2011, 6(11):e27512.
21. Cheng X., Eisenbraun M., Xu Q., Zhou H., Kulkarni D., Subbarao K., et al. H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines. PLoS ONE 2009, 4(2):e4436.
22. Belser J.A., Szretter K.J., Katz J.M., Tumpey T.M. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 2009, 73:55-97.
23. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3(1):e1501.
24. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28:4771-4776.
25. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354(October (9186)):1277-1282.
26. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005, 79:11788-11800.
27. Zeng H., Goldsmith C., Thawatsupha P., Chittaganpitch M., Waicharoen S., Zaki S., et al. Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells. J Virol 2007, 81:12439-12449.
28. Mozdzanowska K., Furchner M., Washko G., Mozdzanowski J., Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997, 71:4347-4355.
29. WHO Antigenic and genetic characteristics of A(H5N1), A(H7N3), A(H9N2) and variant influenza viruses and candidate vaccine viruses developed for potential use in human vaccines 2013.
30. Belser J.A., Blixt O., Chen L.M., Pappas C., Maines T.R., Van Hoeven N., et al. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci U S A 2008, 105:7558-7563.
31. Pappas C., Matsuoka Y., Swayne D.E., Donis R.O. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol 2007, 14:1425-1432.
32. Min J.Y., Vogel L., Matsuoka Y., Lu B., Swayne D., Jin H., et al. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 2010, 84:11950-11960.
33. Talaat K.R., Karron R.A., Callahan K.A., Luke C.J., DiLorenzo S.C., Chen G.L., et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 2009, 27:3744-3753.
34. Couch R.B., Patel S.M., Wade-Bowers C.L., Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 2012, 7(12):e49704.
35. Bart S.A., Hohenboken M., Della Cioppa G., Narasimhan V., Dormitzer P.R., Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014, 6:234ra55.
36. Couch R.B., Decker W.K., Utama B., Atmar R.L., Nino D., Feng J.Q., et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a h5, h7 and h9 vaccines in humans. PLoS ONE 2012, 7(12):e50830.
37. Cox R.J., Major D., Hauge S., Madhun A.S., Brokstad K.A., Kuhne M., et al. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir Viruses 2009, 3:107-117.
38. Goff P.H., Krammer F., Hai R., Seibert C.W., Margine I., Garcia-Sastre A., et al. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J Virol 2013, 87:8235-8240.
39. Kreijtz J.H., Wiersma L.C., De Gruyter H.L., Vogelzang-van Trierum S.E., van Amerongen G., Stittelaar K.J., et al. A single immunization with modified vaccinia virus ankara-based influenza virus H7 vaccine affords protection in the influenza A (H7N9) pneumonia ferret model. J Infect Dis 2015, 211:791-800.
40. Katz J.M., Hancock K., Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011, 9:669-683.
41. + T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2012, 90:540-552.
42. Belser J.A., Tumpey T.M. Tropism of H7N9 influenza viruses in the human respiratory tract. Lancet Respir Med 2013, 1:501-502.
43. Watanabe T., Watanabe S., Neumann G., Kida H., Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 2002, 76:767-773.